|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
1995-10-4
|
|
pubmed:abstractText |
The Wilms' tumor-suppressor gene product WT1 coimmunoprecipitates with p53 from baby rat kidney (BRK) cells and Wilms' tumor specimens, and expression of WT1 in BRK cells is associated with increased levels of endogenous wild-type p53 protein. To study the effect of WT1 on p53 function, we cotransfected expression constructs into Saos-2 cells, an osteosarcoma cell line without endogenous expression of either gene. Expression of WT1 resulted in increased steady-state levels of p53, attributable to a prolongation in protein half-life, and associated with protection against papillomavirus E6-mediated degradation of p53. This effect mapped to zinc fingers 1 and 2 of WT1 and was not observed with the closely related EGR1 protein. The stabilized p53 demonstrated enhanced binding to its target DNA sequence and increased trans-activation of a promoter containing this RGC site, but reduced transcriptional repression of a TATA-containing promoter lacking this site. Expression of WT1 inhibited p53-mediated apoptosis triggered by UV irradiation or by expression of temperature-sensitive p53 in the wild-type conformation, but did not affect p53-mediated cell cycle arrest. We conclude that WT1 protein can stabilize p53, modulate its trans-activational properties, and inhibit its ability to induce apoptosis. This effect may contribute to the elevated levels of wild-type p53 protein that are observed in Wilms' tumors.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0890-9369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
9
|
|
pubmed:geneSymbol |
WT1,
p53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2143-56
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:7657166-Animals,
pubmed-meshheading:7657166-Apoptosis,
pubmed-meshheading:7657166-Base Sequence,
pubmed-meshheading:7657166-Cell Line,
pubmed-meshheading:7657166-Cell Line, Transformed,
pubmed-meshheading:7657166-DNA,
pubmed-meshheading:7657166-DNA-Binding Proteins,
pubmed-meshheading:7657166-Genes, Wilms Tumor,
pubmed-meshheading:7657166-Genes, p53,
pubmed-meshheading:7657166-Humans,
pubmed-meshheading:7657166-Molecular Sequence Data,
pubmed-meshheading:7657166-Oncogene Proteins, Viral,
pubmed-meshheading:7657166-Rats,
pubmed-meshheading:7657166-Repressor Proteins,
pubmed-meshheading:7657166-Transcription, Genetic,
pubmed-meshheading:7657166-Transcription Factors,
pubmed-meshheading:7657166-Transcriptional Activation,
pubmed-meshheading:7657166-Transfection,
pubmed-meshheading:7657166-Tumor Cells, Cultured,
pubmed-meshheading:7657166-Tumor Suppressor Protein p53,
pubmed-meshheading:7657166-WT1 Proteins,
pubmed-meshheading:7657166-Wilms Tumor,
pubmed-meshheading:7657166-Zinc Fingers
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
|
|
pubmed:affiliation |
Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
